Warning Letter — GSC Products, LLC
The FDA issued a warning letter to GSC Products, LLC regarding the distribution of unapproved and misbranded drug products. The letter indicates that the company marketed products with therapeutic claims that lack FDA approval and failed to comply with statutory requirements.
This action affects GSC Products, LLC, its executive leadership, and internal departments responsible for product labeling, marketing, and regulatory compliance.
The issuance of a warning letter from CDER signifies serious regulatory deviations that could lead to further enforcement actions, such as seizures or injunctions, if not remediated. This case underscores the FDA's ongoing focus on unapproved drug claims and the necessity for firms to strictly adhere to the Federal Food, Drug, and Cosmetic Act regarding product classification and marketing.
Regulatory and QA teams should conduct a thorough review of all product labeling and marketing materials to ensure no unauthorized therapeutic claims are being made. Firms should also verify that all drug products are properly listed with the FDA and manufactured in accordance with current Good Manufacturing Practice (cGMP) standards.
FDA Warning Letter issued to: GSC Products, LLC. 05/18/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gsc-products-llc-729653-05182026
Open in openFDA / FDA.gov